🇺🇸 FDA
Patent

US 9273143

Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody

granted A61KA61K2039/505A61K2039/507

Quick answer

US patent 9273143 (Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody) held by REGENERON PHARMACEUTICALS, INC. expires Mon Feb 25 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Mar 01 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 25 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
24
CPC classes
A61K, A61K2039/505, A61K2039/507